Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.
about
Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failureBasic Concepts in Population Modeling, Simulation, and Model-Based Drug DevelopmentModeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database.Osteoarthritis disease progression model using six year follow-up data from the osteoarthritis initiative.A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies.Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.Population pharmacodynamics of romazarit.Clinical pharmacology = disease progression + drug actionModeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease.Expanding clinical applications of population pharmacodynamic modelling.Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.Models for disease progression: new approaches and uses.Disease progression and neuroscience.Whither pharmacometrics?: present state and future choices.Disease Progression Modeling: Key Concepts and Recent DevelopmentsDevelopment of a placebo effect model combined with a dropout model for bipolar disorder.Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.Interpreting the results of Parkinson's disease clinical trials: time for a change.Bivariate or composite plots of endpoints.An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab.Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.
P2860
Q28346899-2B12FEC9-A447-4B41-BBE4-023C2A90B6EEQ29013931-D9CD7EEB-B7B7-48A9-9B85-653D0E46D7FAQ30567951-65F0EE76-56FB-4DBF-AE2A-6273816CC76EQ30850701-5E191D4C-B08C-445F-8120-784F87B5CF69Q30983125-B35E090D-4959-4904-945F-258F236C8380Q33524423-40F3F09C-F9EB-446E-B0B1-7F5EC771F81CQ34123784-B65555A6-5607-4B53-84B0-36C7EA47D5F7Q34347065-22EE552D-5804-4DD8-8B0C-B388DE49D65CQ34953659-8129B1FB-BAC9-4427-9F51-9AAB0787D059Q35233391-20CC90CD-7055-4292-8042-9032FCE0E4D6Q35803310-E2338FC6-C43C-482F-A574-30186E763688Q35825455-99FF3816-226D-4D7B-8B18-03FEED00AB80Q36952913-03B38143-546D-495E-90DD-2DF4D82DF148Q37886138-32FBE9B9-C452-4636-9E95-CCED3A828EB3Q38012237-50049089-E09B-45C7-932E-4BD8A80A423DQ38099584-7CA212A2-2571-4CFD-8E65-CAEE6B886D42Q39189602-6AE5BD19-55D3-4C94-9F61-B8F44FE5A3BBQ41639443-7FFE7651-8E03-4FBC-9A8A-A2702FCA528BQ43480141-B936F34E-5FC3-4750-A580-E523B12D4937Q43754366-9C4809E2-9A4E-4BC9-A806-F19B2502DB86Q45797972-988B2452-AFB0-4EB0-BF0F-F4FB3013397CQ46124057-16D9884A-8D59-4C9E-9C26-97CF00F74A43Q53356299-1E250CAD-6277-4C7C-B0D6-2E2FAF1DBA10Q54942565-BA914F8A-2390-4189-AB5F-CD729A0679B3Q55411843-862332DC-290B-4EFA-AD51-6CA3F06A3F52
P2860
Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1992
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Results and validation of a po ...... patients treated with tacrine.
@en
Results and validation of a po ...... patients treated with tacrine.
@nl
type
label
Results and validation of a po ...... patients treated with tacrine.
@en
Results and validation of a po ...... patients treated with tacrine.
@nl
prefLabel
Results and validation of a po ...... patients treated with tacrine.
@en
Results and validation of a po ...... patients treated with tacrine.
@nl
P2860
P356
P1476
Results and validation of a po ...... patients treated with tacrine.
@en
P2093
P2860
P304
11471-11475
P356
10.1073/PNAS.89.23.11471
P407
P577
1992-12-01T00:00:00Z